Open
Apexigen是一家癌癥免疫療法平臺公司，藥廠客戶可利用其多種蛋白質(zhì)標(biāo)靶候選物，開發(fā)成黑色素瘤、消化道癌等適應(yīng)癥之細(xì)胞抗體。
Apexigen is a biopharmaceutical company focused on innovative cancer antibody therapies. Using its APXiMAB™ platform, the company developed programs like sotigalimab and aided partners in discovering therapies for challenging molecular targets, exemplified by Novartis' FDA-approved Beovu®. Numerous other APXiMAB-based programs are progressing in mid- to late-stage clinical development.
Apexigen is a biopharmaceutical company focused on innovative cancer antibody therapies. Using its APXiMAB™ platform, the company developed programs like sotigalimab and aided partners in discovering therapies for challenging molecular targets, exemplified by Novartis' FDA-approved Beovu®. Numerous other APXiMAB-based programs are progressing in mid- to late-stage clinical development.